Irbesartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 29300-216

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Irbesartan And Hydrochlorothiazide (NDC 29300-216). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 01

This appears to be a study comparing the effectiveness of various treatments containing Irbesartan and/or Hydrochlorothiazide in reducing systolic blood pressure (SBP) in patients. The chart shows the probability of achieving an SBP of less than 140 mmHg in patients from two separate initial therapy studies labeled V and VI. The X-axis represents baseline SBP measurements and the Y-axis represents the probability of achieving the target SBP.*

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 02

This appears to be a description of a study involving the use of Irbesartan and Hydrochlorothiazide for patients with high blood pressure. Figure 1b displays the probability of patients achieving a systolic blood pressure reading of under 130 mmHg after 8 weeks of therapy. However, no further information is available.*

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 03

The text describes a figure, labeled as Figure 2a, which displays the probability of achieving a DBP (diastolic blood pressure) of less than 90 mmHg in patients in hydrochlorothiazide Study V and valsartan study V, and in furosemide and hydrochlorothiazide Study V and olmesartan study VI. The x-axis shows the baseline DBP in mmHg, and the y-axis shows the probability of achieving the target DBP.*

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 04

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 05

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 06

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 07

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 08

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 09

This text is a company name: "UNICHEM PHARMACEUTICALS (USA). INC."*

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 10

This is a medication containing 150mg of Irbesartan USP and 12.5mg of Hydrochlorothiazide USP in a film-coated tablet. The recommended dosage can be found in the accompanying package insert. The tablets should be stored at controlled room temperature and kept away from children. The tablets are manufactured by Unichem Laboratories Ltd, located in Ghaziabad, India, and manufactured for Unichem Pharmaceuticals (USA), Inc. in East Brunswick, NJ.*

FDA Label Image

33edeed5 8a7f 4753 8729 84714238a5c5 11

This is a description of a medication called Irbesartan, which comes in the form of tablets. The tablets contain 300 mg of Irbesartan and 12.5 mg of Hydrochlorothiazide. The usual dosage can be found in the accompanying instructions. This medication should be kept out of reach of children and stored at controlled room temperature. The tablets are manufactured by UNICHEM PHARMACEUTICALS (USA), INC. The company's address is provided and it is revealed that the medication was manufactured by UNICHEM LABORATORIES LTD. in India.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.